Scarica l'app Stockscreener
6.16
7.92%
-0.53
Dopo l'orario di chiusura:
6.29
0.13
+2.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.69
Aprire:
$6.74
Volume 24 ore:
1.32M
Relative Volume:
0.88
Capitalizzazione di mercato:
$281.62M
Reddito:
$27.10M
Utile/perdita netta:
$-24.31M
Rapporto P/E:
-7.4217
EPS:
-0.83
Flusso di cassa netto:
$-33.33M
1 W Prestazione:
-19.16%
1M Prestazione:
-0.96%
6M Prestazione:
-36.10%
1 anno Prestazione:
-69.97%
Intervallo 1D:
$6.10
$6.82
Intervallo di 1 settimana:
$6.10
$7.62
Portata 52W:
$5.68
$22.90
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
10865 ROAD TO THE CURE, SAN DIEGO, CA
Confronta CAPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.16 | 306.30M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Iniziato | Alliance Global Partners | Buy |
| 2025-06-26 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | Roth Capital | Buy |
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
What institutional flow reveals about Capricor Therapeutics Inc.July 2025 Retail & AI Based Buy/Sell Signal Reports - newser.com
Can trapped investors hope for a rebound in Capricor Therapeutics Inc.Weekly Risk Summary & Precise Buy Zone Tips - newser.com
Historical volatility pattern of Capricor Therapeutics Inc. visualizedBull Run & Fast Momentum Entry Tips - newser.com
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Below 50-Day Moving AverageHere's What Happened - MarketBeat
How Capricor Therapeutics Inc. stock reacts to job market dataQuarterly Investment Review & Safe Entry Momentum Tips - newser.com
How analysts rate Capricor Therapeutics Inc. stock todayJuly 2025 Weekly Recap & Reliable Intraday Trade Plans - newser.com
Heatmap analysis for Capricor Therapeutics Inc. and competitors2025 Price Momentum & Community Verified Trade Alerts - newser.com
Capricor Therapeutics : Investor PresentationOctober 2025 - MarketScreener
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Capricor Therapeutics (CAPR): Evaluating Valuation After Lawsuit and FDA Decision Shake Investor Confidence - Yahoo Finance
Capricor Therapeutics (CAPR): Assessing Valuation After FDA Setback and Class Action Complaint - Sahm
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Exploring a 170% Upside Potential in Biotechnology - DirectorsTalk Interviews
Is a relief rally coming for Capricor Therapeutics Inc. holdersWeekly Risk Summary & Daily Profit Focused Screening - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is FDA Embrace of HOPE-3 Data Shaping the Investment Thesis for Capricor Therapeutics (CAPR)? - Sahm
Will Capricor Therapeutics Inc. (4LN2) stock outperform energy sector in 2025Weekly Loss Report & Community Driven Trade Alerts - newser.com
CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Capricor Therapeutics Inc Stock Analysis and ForecastMomentum Stock Picks & Minimal Investment Capital Gains - earlytimes.in
What drives Capricor Therapeutics Inc 4LN2 stock priceMarket Correction Analysis & Affordable Market Insights - earlytimes.in
Will Capricor Therapeutics Inc. stock see PE expansionInsider Buying & Free Verified High Yield Trade Plans - newser.com
Volume spikes in Capricor Therapeutics Inc. stock – what they meanWeekly Market Report & Daily Technical Forecast Reports - newser.com
Will Capricor Therapeutics Inc. (4LN2) stock profit from AI boom2025 Market Overview & Growth Focused Investment Plans - newser.com
Is Capricor Therapeutics Inc. stock resilient to inflationJuly 2025 Technicals & Community Supported Trade Ideas - newser.com
New Drug for Duchenne Muscular Dystrophy Nears Potential Approval - streetwisereports.com
Capricor Therapeutics Inc. recovery potential after sell off2025 Sector Review & Safe Entry Zone Tips - newser.com
Published on: 2025-10-05 04:39:29 - newser.com
Is Capricor Therapeutics Inc. (4LN2) stock a good hedge against inflation2025 Top Gainers & Community Verified Swing Trade Signals - newser.com
User - FinancialContent
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation - GlobeNewswire
There's Reason For Concern Over Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Massive 26% Price Jump - 富途牛牛
Head to Head Review: Baxter International (NYSE:BAX) and Capricor Therapeutics (NASDAQ:CAPR) - Defense World
Largest borrow rate increases among liquid names - TipRanks
Biotech Secures FDA Alignment on Late-Stage Duchenne Therapy - streetwisereports.com
Biotech Battles FDA, Target Price Shows Potential 90% Gains - streetwisereports.com
Hope On The Horizon As Capricor's HOPE-3 Trial For Duchenne Muscular Dystrophy Nears Data Readout - RTTNews
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Capricor Therapeutics Inc Azioni (CAPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
2,500 |
3,475 |
8,223 |
| Litvack Frank | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
132,382 |
| DUNBAR GEORGE W JR | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
11,306 |
| COLLIER EARL M JR | Director |
Feb 27 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
57,606 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Dec 13 '24 |
Option Exercise |
1.39 |
8,000 |
11,120 |
28,047 |
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):